What this pack is
NAMENDA is the brand name in this record; memantine is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
NAMENDAGeneric namememantine
How this medicine works
In Clinical Pharmacology, this historical label describes memantine hydrochloride as an NMDA-receptor antagonist. It explains one drug-action pathway in the label; it does not predict an individual's cognitive change, suitability, course, tablet count or co-use plan.
Read source: United States ↗Historical public record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- NAMENDA
- Generic name
- memantine
- Dosage-form class
- Film-coated oral tablets: text identities for two historical NAMENDA 60-tablet bottles at 5 mg and 10 mg; two current Lupin generic 60-tablet bottles at 5 mg and 10 mg with official label images, each kept separate by product and NDC
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Historical public label: page updated 1 Nov 2018; SPL v19 published 20 Dec 2024
Memantine hydrochloride 5 mg per tablet; 60-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0456-3205-60
- Form and route
- film-coated oral tablet · oral
- Container
- bottle
- memantine hydrochloride
- 5 mglabelled amount per tablet
- Package
- 60 tablets per bottle
- Labelled appearance
- tan · capsule-shaped tablet · imprint 5 / FL
United States label · Historical public label: page updated 1 Nov 2018; SPL v19 published 20 Dec 2024
Memantine hydrochloride 10 mg per tablet; 60-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0456-3210-60
- Form and route
- film-coated oral tablet · oral
- Container
- bottle
- memantine hydrochloride
- 10 mglabelled amount per tablet
- Package
- 60 tablets per bottle
- Labelled appearance
- gray · capsule-shaped tablet · imprint 10 / FL
United States label · Current U.S. DailyMed ANDA generic label (patient information revised Aug 2025; SPL 29 Dec 2025)
Memantine hydrochloride 5 mg per tablet; 60-tablet bottle
- Product code
- NDC 68180-229-07
- Form and route
- memantine hydrochloride film-coated oral tablet (generic comparator; not a NAMENDA originator-brand pack) · oral
- Container
- 60-tablet prescription bottle label panel
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- memantine hydrochloride
- 5 mglabelled amount per tablet; not an individual's tablet count, titration or switching instruction
- Package
- 60 tablets per bottle
- Labelled appearance
- tan · capsule-shaped, biconvex film-coated tablet · imprint LU / W01
United States label · Current U.S. DailyMed ANDA generic label (patient information revised Aug 2025; SPL 29 Dec 2025)
Memantine hydrochloride 10 mg per tablet; 60-tablet bottle
- Product code
- NDC 68180-230-07
- Form and route
- memantine hydrochloride film-coated oral tablet (generic comparator; not a NAMENDA originator-brand pack) · oral
- Container
- 60-tablet prescription bottle label panel
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- memantine hydrochloride
- 10 mglabelled amount per tablet; not an individual's tablet count, titration or switching instruction
- Package
- 60 tablets per bottle
- Labelled appearance
- gray · capsule-shaped, biconvex film-coated tablet · imprint LU / W02
PACKAGE-VISUAL STATUS
Historical NAMENDA originator-brand images remain withheld; current generic images are identified separately
The historical NAMENDA DailyMed label traces the trade name, 5 mg/10 mg, two historical NDCs, 60-tablet bottles and the U.S. marketing-end date, but no usable one-to-one public originator-brand image was retained, so originator-brand package images are not shown and those packs remain text-only. The two newly shown images explicitly belong to current Lupin ANDA 090051 generic NDC 68180-229-07 and 68180-230-07; they must not be read as NAMENDA originator-brand appearance, authentication or a switching basis.
LABEL READING · NOT A PRESCRIPTION
NAMENDA / memantine label reading: separate the historical originator brand from a current generic first
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module places two source layers side by side without merging them: the historical NAMENDA brand label and the current Lupin generic label with its electronic leaflet. The 5 mg, 10 mg, NDC, 60-tablet count and appearance identify an exact product only; the page provides no individual tablet count, titration, missed-use remedy, initiation, stopping, co-use, switching or purchase plan.
- Check NAMENDA, memantine hydrochloride, 5 mg or 10 mg, NDC, film-coated oral-tablet form and target market together. A shared brand or generic name does not prove that another strength, NAMENDA XR, an oral solution, a combination product or another-market product is interchangeable.
- The 5 mg, 10 mg and “60-tablet bottle” wording identifies these two historical label panels; it does not say how many tablets to use, when to change, whether to make up a missed use or whether splitting is appropriate. Take the current pack, prescription and full medicine list to a pharmacist or prescribing team for any actual-use question.
- Adverse-reaction and interaction sections of the label help frame questions; they do not let a webpage determine the cause of a symptom. Especially with older age, multiple conditions or multiple medicines, do not self-stop, combine, alternate or adjust because of dizziness, confusion, constipation, urine-pH-related wording or package numbers.
- Lupin, NDC 68180-229-07 or 68180-230-07, LU/W01 or LU/W02 and the official current generic label images can help check a bottle in hand, but they are not NAMENDA originator-brand pack images. A caregiver should review the bottle, prescription, all other medicines and supplements together, and must not assemble or substitute an immediate-release tablet, extended-release capsule, oral solution or NAMZARIC combination by comparing milligram numbers.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): NAMENDA memantine-hydrochloride U.S. historical public label (Allergan; page updated 1 Nov 2018; SPL v19 published 20 Dec 2024) ↗Historical public record · reviewed 2026-08-20
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-04DailyMed (NLM): current U.S. Lupin memantine-hydrochloride generic label and exact bottle panels under ANDA 090051 ↗Current regulatory record · reviewed 2026-09-04
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about NAMENDA (memantine). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
NAMENDA is the brand in this record and memantine is the active-ingredient name. Check both with the dosage form (Film-coated oral tablets: text identities for two historical NAMENDA 60-tablet bottles at 5 mg and 10 mg; two current Lupin generic 60-tablet bottles at 5 mg and 10 mg with official label images, each kept separate by product and NDC) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): NAMENDA memantine-hydrochloride U.S. historical public label (Allergan; page updated 1 Nov 2018; SPL v19 published 20 Dec 2024) ↗Historical public record · reviewed 2026-08-20
- DailyMed (NLM): current U.S. Lupin memantine-hydrochloride generic label and exact bottle panels under ANDA 090051 ↗Current regulatory record · reviewed 2026-09-04
HOW IT WORKS · NOT A TREATMENT PLAN
How memantine hydrochloride works: the historical label describes an NMDA-receptor antagonist
- NMDA is the name of a receptor, and “antagonist” describes the direction of a drug's related action. This mechanism term alone cannot tell whether a person is suitable, when an effect will occur, how long use should continue or whether a product should be changed.
- Being described as cognition-related, having similar label terms or appearing on the same medicine list does not establish that products can be self-combined, alternated or substituted. A professional should review the exact products, current target-market labels, prior reactions and full medicine list.
- If a caregiver notices a marked acute change, fall risk, altered consciousness or uncertainty about what to do, use local urgent and professional care pathways; do not use a mechanism explanation or historical label as a rule for self-adjusting, stopping or making up use.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): NAMENDA memantine-hydrochloride U.S. historical public label (Allergan; page updated 1 Nov 2018; SPL v19 published 20 Dec 2024) ↗Historical public record · reviewed 2026-08-20
- DailyMed (NLM): current U.S. Lupin memantine-hydrochloride generic label and exact bottle panels under ANDA 090051 ↗Current regulatory record · reviewed 2026-09-04
- DailyMed (NLM): current U.S. Lupin memantine-hydrochloride electronic label PDF ↗Current regulatory record · reviewed 2026-09-04
SOURCE-TRACEABLE ARCHIVE
NAMENDAmemantine
This page links to public primary-source material for NAMENDA. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the historical label
This historical NAMENDA public label lists Initial U.S. Approval: 2003. It locates this U.S. historical archive only; it does not establish approval, supply, sale eligibility, originator/generic relationship or individual suitability in another market.
DailyMed (NLM): NAMENDA memantine-hydrochloride U.S. historical public label (Allergan; page updated 1 Nov 2018; SPL v19 published 20 Dec 2024) ↗U.S. marketing-start date listed in historical-label product data
Historical-label product data list 16 Oct 2003 as the U.S. marketing-start date for NAMENDA tablets. This is a historical product record, not evidence of current availability, stock, individual use or another-market status.
DailyMed (NLM): NAMENDA memantine-hydrochloride U.S. historical public label (Allergan; page updated 1 Nov 2018; SPL v19 published 20 Dec 2024) ↗U.S. marketing-end date listed in historical-label product data
Product data in this historical label list 31 Oct 2025 as the U.S. marketing-end date. This page therefore does not describe NAMENDA as currently purchasable, marketed, interchangeable or still supplied in the United States. Questions about a current product require the current target-market regulatory record and a professional.
DailyMed (NLM): NAMENDA memantine-hydrochloride U.S. historical public label (Allergan; page updated 1 Nov 2018; SPL v19 published 20 Dec 2024) ↗Current Lupin generic SPL lists two exact 60-tablet bottles
The current ANDA 090051 public label separately lists 5 mg / NDC 68180-229-07 / LU-W01 and 10 mg / NDC 68180-230-07 / LU-W02 with exact package images and patient information. It is a current generic comparator, not a NAMENDA originator-brand pack or permission for an individual switch.
DailyMed (NLM): current U.S. Lupin memantine-hydrochloride generic label and exact bottle panels under ANDA 090051 ↗
MARKET SCOPE
Market-record boundary
United States
The NAMENDA originator-brand label lists a marketing end of 31 Oct 2025; the Lupin generic label is a current comparatorTwo historical NAMENDA 60-tablet bottles at 5 mg and 10 mg retain text identity only, and product data in that historical label list a U.S. marketing end date of 31 Oct 2025. Two current Lupin ANDA 090051 60-tablet bottles are shown separately with exact NDCs, imprints and official images. The generic images are not presented as originator-brand appearance and do not establish stock, purchase, switching or supply.
Mainland China, EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from this U.S. historical label; each market requires separate checking against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Do NAMENDA 5 mg, 10 mg or a 60-tablet bottle mean that tablet count can be self-adjusted, or that a person can switch to NAMENDA XR or alternate with another cognition-related medicine?
No. These words only identify exact tablets and bottles in a historical label. A shared brand, generic name, therapeutic area or similar milligram number does not establish self-adjustment, splitting, make-up use, combining, alternating or substitution; take the current pack, prescription and complete medicine list to a pharmacist or prescribing team.
Are the Lupin bottle images on this page NAMENDA originator-brand packages?
No. They are exact panels tied to NDC 68180-229-07 and 68180-230-07 in a current U.S. generic label and only help check those generic bottles. The historical NAMENDA originator-brand packages remain text-only because no usable one-to-one public image was retained.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.